Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2024

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of March 31, 2024 and December 31, 2023 were as follows:


	March 31, 2024		December 31, 2023
Accrued compensation expenses	$	21,423	$	716,307
Accrued research and development		2,763,110		2,263,934
Accrued professional fees		316,507		58,388
Other accounts payable and accrued expenses		9,202		3,809
Total	$	3,110,242	$	3,042,438